Komori
Changes in Officers4569KYORIN Pharmaceutical Co.,Ltd.Pharmaceuticals

Our Subsidiary: Kyorin Remedio Co., Ltd. — Notice of Changes in Officers

奥積 Ryota (奥積 亮太), General Manager to the President and Special Assignment Officer of the subsidiary, is scheduled to be nominated as a director. The appointment will be formally decided at the extraordinary general meeting of shareholders scheduled for 1 May 2026.

Worth reading
23Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Who is moving to which position

Resolved 24 April 2026

Incoming appointee

1 item
Scheduled Appointment Date1 May 2026 (scheduled to be decided at the extraordinary general meeting of shareholders of キョーリン リメディオ株式会社 to be held on the same day)
Okuzumi Ryota (奥積 亮太)
Previous positionGeneral Manager to the President, Special Assignment Officer
New positionDirectors
Shareholders’ meeting approvalRequired. Proposal: Election of Directors (not explicitly stated in the body); scheduled date: 1 May 2026 (extraordinary general meeting of shareholders)
Who is moving to which position
ItemDetails
Resolution date24 April 2026
Scheduled Appointment Date1 May 2026 (scheduled to be decided at the extraordinary general meeting of shareholders of キョーリン リメディオ株式会社 to be held on the same day)
Name of appointeeOkuzumi Ryota (奥積 亮太)
Appointee's new positionDirectors
Appointee's previous positionGeneral Manager to the President, Special Assignment Officer
Subject to Approval by the General Meeting of ShareholdersRequired. Proposal: Election of Directors (not explicitly stated in the body); scheduled date: 1 May 2026 (extraordinary general meeting of shareholders)
Items this document does not state (15)
Date of departureAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeName of departing officerFormer position of departing officerNew position of departing officerReason for departureWhether the incumbent will remain in officeReason for changeReasons for appointmentNumber of directors after the changeFiling as an independent officerDetails of organizational changesChange in Corporate Governance Structure

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

No reason for the changes or appointments is stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Our Subsidiary: Kyorin Remedio Co., Ltd. — Notice of Changes in Officers | KYORIN Pharmaceutical Co.,Ltd. (4569) timely disclosure | Komori